Trial Results Support Frontline Use of T-DM1 in HER2 ‐Positive Metastatic Breast Cancer

Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2 ‐positive metastatic breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

ConclusionsLuminal A tumor was the most prevalent subtype, while HER2-positive was the least prevalent. Luminal A tumors were mostly associated with lobular carcinomas. HER2-positive and triple negative tumors showed higher histological grade and larger tumor size at the time of diagnosis. These tumors were commonly found in women below the age of 50 years. Carcinoma-in-situ was less prevalent in HER2-positive tumors. Furthermore, a strong association was observed between axillary lymph node status and molecular subtypes.
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research
Authors: Han RH, Dunn GP, Chheda MG, Kim AH Abstract Metastases from melanoma, lung and breast cancer are among the most common causes of intracranial malignancy. Standard of care for brain metastases include a combination of surgical resection, stereotactic radiosurgery, and whole-brain radiation. However, evidence continues to accumulate regarding the efficacy of molecularly-targeted systemic treatments and immunotherapy. For non-small cell lung cancer (NSCLC), numerous clinical trials have demonstrated intracranial activity for inhibitors of EGFR and ALK. Patients with melanoma brain metastases may benefit from ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conclusions: The novel lncRNA HOXC-AS3 acts as a miR-3922-5p sponge to upregulate PPP1R1A protein expression, and thus results in promoting breast cancer metastasis. HOXC-AS3 could be a novel therapeutic target for breast cancer therapeutics. PMID: 31797701 [PubMed - as supplied by publisher]
Source: Cancer Investigation - Category: Cancer & Oncology Tags: Cancer Invest Source Type: research
The FDA approved FoundationOne CDx as a companion diagnostic for alpelisib in combination with fulvestrant for the treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
AbstractSynergism in action of tucatinib and trastumab is reported in breast cancer management. However, its molecular basis is yet to be determined. In this context we attempted to provide an explanation at the molecular level by performing in silico experimentation and coupling its result with already available published observations. Our study will provide basis for planning further experimental study for unravelling the truth.
Source: Indian Journal of Clinical Biochemistry - Category: Biochemistry Source Type: research
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage 0 Breast Cancer AJCC v8;   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Anatomic Stage 0 Breast Cancer AJCC v8;   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC&n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Advanced Breast Cancer Interventions:   Biological: BAT8001 for injection;   Drug: Lapatinib;   Drug: Capecitabine Sponsor:   Bio-Thera Solutions Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin